Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.46 |
| ▸ | CDK7 | P50613 | 9/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655326 | 0.86 | CHEK1 (0.60) | CHEK1CDK7 | |
| SCHEMBL13655325 | 0.83 | MC4R (0.40) | CHEK1CDK7KDM4EMEN1ALDH1A1 | |
| SCHEMBL13655332 | 0.83 | PIP5K1C (0.40) | CHEK1CDK7KDM4EMEN1ALDH1A1 | |
| SCHEMBL13655346 | 0.82 | CHEK1 (0.46) | CHEK1CDK7PIP5K1C | |
| SCHEMBL13655330 | 0.79 | CLK2 (0.39) | CHEK1CDK7PIP5K1C | |
| SCHEMBL13655342 | 0.79 | TERT (0.41) | CHEK1CDK7PARP1KDM4EMEN1 | |
| SCHEMBL13655331 | 0.78 | KDM4E (0.43) | CHEK1CDK7KDM4EMEN1ALDH1A1 | |
| SCHEMBL13655343 | 0.76 | CHEK1 (0.45) | CHEK1CDK7PARP1PIP5K1C | |
| SCHEMBL13655345 | 0.72 | CLK2 (0.42) | CHEK1CDK7PARP1ALDH1A1MAPT | |
| SCHEMBL13655335 | 0.72 | PIP5K1C (0.44) | CHEK1CDK7PARP1PIP5K1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8784774-B2 | Labeled molecular imaging agents and methods of use | GENERAL ELECTRIC COMPANY (US) | 2014-07-22 | — | — | US | disclosed |
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MAPT, PSEN2, PSEN1 | CHEK1 1733/4885CDK7 281/4885PARP1 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.